
About
Axcelead Drug Discovery Partners, Inc. provides drug discovery and development services for biotechnology and pharmaceutical partners, with work spanning target discovery through IND enabling. It is based in Fujisawa, Kanagawa, Japan and was formed in 2017 as a Takeda spin-out.
Services
Integrated drug discovery
End-to-end drug discovery services from target discovery to IND-enabling translational research.
Assays & in vitro testing
Axcelead Booster
Data-driven drug candidate generation using legacy pharma projects, proprietary data, AI tools, and discovery platforms.
Target identification / validation
Supports identification of novel drug targets using human data-driven transcriptomics and proteomics, and validates targets with human samples and disease models.
Assays & in vitro testing
Hit identification / characterization
Provides HTS strategy design, assay development, hit characterization, compound library screening, and hit prioritization.
Assays & in vitro testing
Lead generation / optimization
Supports medicinal and analytical chemistry, biology, DMPK, safety evaluation, and in silico design for lead generation and optimization.
Assays & in vitro testing
Candidate selection
Evaluates optimized compounds for IND feasibility using PK/PD/E, TK/TD, modeling and simulation, human PK/effective dose prediction, and safety assessment.
ADME, DMPK & toxicology
IND enabling
Provides Smart-IND project support from candidate selection to IND filing, including strategy, project management, non-GMP bulk preparation, and modality-specific planning.
ADME, DMPK & toxicology
Chemistry
Offers medicinal, computational, synthetic, and analytical chemistry, including hit expansion, lead generation, and lead optimization.
Targeted protein degradation
Supports TPD drug discovery at the preclinical stage with specialized chemistry and assay systems.
RNA-targeted small molecules
Provides integrated discovery support for RNA-targeted small molecule programs at the preclinical stage.
Omics
Uses omics technologies to link genes, proteins, and metabolites for biological insight.
Assays & in vitro testing
Bioinformatics
Converts omics and genomics data into actionable insights for drug discovery.
Assays & in vitro testing
In Vitro/In Vivo Pharmacology
Offers pharmacology support as part of its technology platform.
Assays & in vitro testing
Genetically Modified Animal
Uses genetically modified animal models as a technology platform.
Assays & in vitro testing
- Lead time
- 2–3 business days · Under 12 months · 6 months · 1 year
- What to send
- Diseases of interest, target classes, or specific targets · First Name · Last Name · Email · Organization / Company
Capabilities
- Processes
- Small molecule · Peptide · Oligonucleotide · Cell therapy · Small molecules · HTS · Peptides · Oligonucleotides · In vivo
- Capacity
- 1.2+ million compounds · 1,000 pharma-originated legacy projects · 700+ HTS experiences · 96 parallel syntheses over 5 to 10 days · More than 50 projects for 5 years · 7 candidates · 1 IND · About 240 employees · 1.5 million compounds
Equipment
- High throughput screening
- GPU machines
- 2000 CPU cluster machines
Industries served
- Biotech
- Pharmaceuticals
- Academia
- Public institutions
Company
- Type
- CRO
- Founded
- 2017
- Team
- About 240
Locations
- Based in
- Kanagawa, Japan
- Sites
- Fujisawa, Japan · Kanagawa, Japan · Fujisawa, Kanagawa, Japan
- Serves
- biotechnology and pharmaceutical partners, corporate, start-up, academia, and public institutions, Japan, around the world
Similar labs
Work here? Claim this listing